Future: Dedicated NASH Phase 3 Trial Expected Timeline IF Retatrutide Approved for Obesity/Diabetes (2028): 2027-2028: Dedicated NASH Phase 3 trial begins Population: Biopsy-confirmed NASH with fibrosis (F1-F3) Primary endpoint: NASH resolution without worsening fibrosis Baseline and Week 72-96 liver biopsies Duration: 18-24 months minimum 2029-2030: Trial results published 2030-2031: FDA approval decision for NASH indication Why This Matters Current Reality: Only one FDA-approved medication exists for NASH resmetirom (Rezdiffra), approved March 2024
This story originally said a vial of Zepbound cost $500 when purchased directly from the supplier
That said, it is still a good idea to keep an eye on your pet after each dose and check with your veterinarian if you notice anything unusual, even though adverse reactions are considered very rare
Biomed Pharmacother 1(108):952962 Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB (2008) The molecular basis for the delayed absorption of the once-daily human GLP-1 analoge, Liraglutide
Recently reclassed from within the Dendrophila family, they share some physical traits such as similar colouring and being rear-fanged